Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CLDX Celldex Therapeutics

Trading 03-23 13:52:21 EDT

32.43

+1.53

+4.94%

High34.51	Low31.90	Vol950.69K
Open32.80	D1 Closing30.90	Amplitude8.45%
Mkt Cap2.15B	Tradable Cap1.73B	Total Shares66.45M
T/O31.38M	T/O Rate1.79%	Tradable Shares53.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CLDX","market":"US","secType":"STK","nameCN":"Celldex Therapeutics","latestPrice":32.425,"timestamp":1774288332213,"preClose":30.9,"halted":0,"volume":950693,"delay":0,"changeRate":0.049352750809061444,"floatShares":53206696,"shares":66449471,"eps":-3.9,"marketStatus":"Trading","change":1.525,"latestTime":"03-23 13:52:21 EDT","open":32.798,"high":34.51,"low":31.9,"amount":31375734.388702,"amplitude":0.084466,"askPrice":32.5,"askSize":312,"bidPrice":32.4,"bidSize":17,"shortable":3,"etf":0,"ttmEps":-3.9,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774296000000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":515304000000,"exchange":"NASDAQ","adjPreClose":30.9,"preHourTrading":{"tag":"盘前","latestPrice":32.92,"preClose":30.9,"latestTime":"09:27 EDT","volume":6208,"amount":197167.371264,"timestamp":1774272470051,"change":2.02,"changeRate":0.065372,"amplitude":0.081877},"postHourTrading":{"tag":"盘后","latestPrice":30.91,"preClose":30.9,"latestTime":"19:43 EDT","volume":823252,"amount":25442007.3739,"timestamp":1774050226433,"change":0.01,"changeRate":0.000324,"amplitude":0.035275},"volumeRatio":1.134422,"impliedVol":0.5468,"impliedVolPercentile":0.4661},"requestUrl":"/m/hq/s/CLDX/wiki","defaultTab":"wiki","newsList":[{"id":"2621836200","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2621836200","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621836200?lang=en_us&edition=fundamental","pubTime":"2026-03-24 01:29","pubTimestamp":1774286997,"startTime":"0","endTime":"0","summary":"WeRide  reported on Monday a narrower net loss in Q4 as revenue jumped from a year ago.Shares advanced 6.6% as intraday trading volume rose to over 13.7 million from a daily average of roughly 3.97 million.Insmed  said a phase 3b study of Arikayce, as part of a multidrug regimen to treat patients with Mycobacterium avium complex lung infection, who have not started antibiotics, has met its primary and secondary endpoints.Shares rose 4%, with intraday trading volume of more than 2.01 million against a daily average of about 2.38 million.Wolfe Research upgraded Celldex Therapeutics  to outperform from peer perform.Shares rose 3.5% as intraday trading volume increased to over 902,000 from a daily average of about 847,000.Price: 31.94, Change: +1.04, Percent Change: +3.37","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LU0109394709.USD","LU0889565916.HKD","LU0053671581.USD","INSM","CLDX","LU0320765992.SGD","BK4609","WRD","BK4124","00800"],"gpt_icon":1},{"id":"2621723077","title":"Wolfe Research Upgrades Celldex Therapeutics to Outperform From Peer Perform, PT is $44","url":"https://stock-news.laohu8.com/highlight/detail?id=2621723077","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621723077?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:21","pubTimestamp":1774261319,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average rating of buy and mean price target of $54.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"gpt_icon":0},{"id":"2621774687","title":"Celldex upgraded to Outperform from Peer Perform at Wolfe Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2621774687","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621774687?lang=en_us&edition=fundamental","pubTime":"2026-03-23 17:45","pubTimestamp":1774259108,"startTime":"0","endTime":"0","summary":"Wolfe Research upgraded Celldex (CLDX) to Outperform from Peer Perform with a $44 price target The firm sees a better catalyst setup for the shares...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-upgraded-to-outperform-from-peer-perform-at-wolfe-research-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2616635228","title":"Celldex Therapeutics Is Maintained at Neutral by Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2616635228","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616635228?lang=en_us&edition=fundamental","pubTime":"2026-03-03 01:21","pubTimestamp":1772472060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 02, 2026 12:21 ET (17:21 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX"],"gpt_icon":0},{"id":"2616599123","title":"Cantor Fitzgerald Reaffirms Their Buy Rating on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616599123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616599123?lang=en_us&edition=fundamental","pubTime":"2026-03-02 23:35","pubTimestamp":1772465756,"startTime":"0","endTime":"0","summary":"Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Celldex yesterday and set a price target of $67.00. According to TipRanks, Klus...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-reaffirms-their-buy-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2616287807","title":"Celldex presents new data from Phase 2 ColdU, SD Open Label Extension","url":"https://stock-news.laohu8.com/highlight/detail?id=2616287807","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616287807?lang=en_us&edition=fundamental","pubTime":"2026-03-02 00:35","pubTimestamp":1772382906,"startTime":"0","endTime":"0","summary":"Celldex (CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension, highlighting that retreatment with barzolvolimab lea...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celldex-presents-new-data-from-phase-2-coldu-sd-open-label-extension-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celldex-presents-new-data-from-phase-2-coldu-sd-open-label-extension-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SD","CLDX","BK4213","BK4139"],"gpt_icon":0},{"id":"2616382019","title":"Celldex reports Phase 2 data showing barzolvolimab retreatment restores strong efficacy in cold urticaria and symptomatic dermographism","url":"https://stock-news.laohu8.com/highlight/detail?id=2616382019","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616382019?lang=en_us&edition=fundamental","pubTime":"2026-03-01 22:45","pubTimestamp":1772376315,"startTime":"0","endTime":"0","summary":"Celldex reports Phase 2 data showing barzolvolimab retreatment restores strong efficacy in cold urticaria and symptomatic dermographism. Celldex Therapeutics Inc. announced new data from the Phase 2 open-label extension of its inducible urticaria program showing that retreatment with barzolvolimab after symptom recurrence produced response rates similar to initial treatment in patients with cold urticaria and symptomatic dermographism. At Week 20 of the extension, 62% of cold urticaria patients and 60% of symptomatic dermographism patients achieved a complete response, and the safety profile was reported as consistent with prior studies. The results were presented as a late-breaking poster at the 2026 American Academy of Allergy, Asthma and Immunology Annual Meeting. Celldex also noted that its global Phase 3 EMBARQ trial in these indications began enrolling in late 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260301:nNDL7Xzny1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU2095319765.USD","BK4588","BK4139","IE00BGHQF748.EUR","CLDX","NDAQ","SG9999014021.USD","SG9999014039.USD","LU2210150020.SGD","LU0314104364.USD","BK4112","IE00BKPKM429.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","SG9999014013.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2616848947","title":"Guggenheim Sticks to Their Buy Rating for Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616848947","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616848947?lang=en_us&edition=fundamental","pubTime":"2026-03-01 01:15","pubTimestamp":1772298933,"startTime":"0","endTime":"0","summary":"Guggenheim analyst Yatin Suneja reiterated a Buy rating on Celldex on February 26 and set a price target of $90.00. The company’s shares closed yes...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-sticks-to-their-buy-rating-for-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2614861705","title":"Celldex reports positive Phase 2 barzolvolimab data in chronic urticaria at AAAAI 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614861705","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614861705?lang=en_us&edition=fundamental","pubTime":"2026-02-28 03:45","pubTimestamp":1772221517,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics Inc. reported additional data from completed Phase 2 trials of barzolvolimab in chronic spontaneous urticaria, cold urticaria and symptomatic dermographism. The company said sustained off-treatment efficacy was observed in chronic spontaneous urticaria after 52 weeks of treatment, with some patients maintaining well-controlled disease and complete response at Week 76, and that quality-of-life and angioedema measures improved in this subset. In the Phase 2 cold urticaria and symptomatic dermographism study, Celldex reported urticaria control and quality-of-life outcomes through Week 20, including complete response rates at Weeks 12 and 20. The results were presented at the AAAAI 2026 Annual Meeting on Feb. 27, 2026, and Celldex also noted that enrollment is complete in its global Phase 3 chronic spontaneous urticaria program and ongoing in its Phase 3 cold urticaria and symptomatic dermographism study.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nNDL3xYb0p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","CLDX","LU2210149790.SGD","LU2210150020.SGD","SG9999014013.SGD","BK4112","SG9999014005.SGD","IE00B3QW5Z07.USD","SG9999014021.USD","NDAQ","BK4585","IE00B64PRP62.GBP","LU0314104364.USD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4588","BK4139"],"gpt_icon":0},{"id":"2614902895","title":"Celldex Therapeutics Price Target Raised to $68.00/Share From $58.00 by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2614902895","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614902895?lang=en_us&edition=fundamental","pubTime":"2026-02-26 22:29","pubTimestamp":1772116140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CLDX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 26, 2026 09:29 ET (14:29 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SF","CLDX"],"gpt_icon":0},{"id":"2614506047","title":"Celldex Therapeutics Inc : Stifel Raises Target Price to $68 From $58","url":"https://stock-news.laohu8.com/highlight/detail?id=2614506047","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614506047?lang=en_us&edition=fundamental","pubTime":"2026-02-26 21:44","pubTimestamp":1772113448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nFWN3ZM20B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2614224045","title":"Morgan Stanley Lifts Price Target on Celldex Therapeutics to $44 From $43, Keeps Overweight Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614224045","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614224045?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:03","pubTimestamp":1772107408,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics (CLDX) has an average rating of overweight and mean price target of $55.38, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CLDX"],"gpt_icon":0},{"id":"2614485590","title":"Celldex Therapeutics: Early EMBARQ Enrollment and 2026 Data Catalysts Underscore Attractive Risk‑Reward and Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614485590","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614485590?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:16","pubTimestamp":1772104566,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Judah Frommer has maintained their bullish stance on CLDX stock, giving a Buy rating yesterday. Judah Frommer has given his ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/celldex-therapeutics-early-embarq-enrollment-and-2026-data-catalysts-underscore-attractive-risk‑reward-and-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/celldex-therapeutics-early-embarq-enrollment-and-2026-data-catalysts-underscore-attractive-risk‑reward-and-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2614588010","title":"Celldex Therapeutics Inc : Morgan Stanley  Raises Target Price to $44.00 From $43.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2614588010","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614588010?lang=en_us&edition=fundamental","pubTime":"2026-02-26 19:05","pubTimestamp":1772103913,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nAZN4SIHP0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2614798011","title":"Barclays Reaffirms Their Sell Rating on Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614798011","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614798011?lang=en_us&edition=fundamental","pubTime":"2026-02-26 17:57","pubTimestamp":1772099850,"startTime":"0","endTime":"0","summary":"Barclays analyst Etzer Darout maintained a Sell rating on Celldex today and set a price target of $24.00. According to TipRanks, Darout is a 5-star...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-sell-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-reaffirms-their-sell-rating-on-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CLDX"],"gpt_icon":0},{"id":"2614055163","title":"Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614055163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614055163?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:02","pubTimestamp":1772053367,"startTime":"0","endTime":"0","summary":"Celldex Q4 net loss hits USD 81.3 million as Q4 revenue totals USD 0.1 million (-89.7%)               Celldex reported a Q4 2025 net loss of USD 81.3 million and FY 2025 net loss of USD 258.8 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL7hgvJ6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","SG9999014005.SGD","LU0314104364.USD","LU2095319765.USD","BK4112","NDAQ","SG9999014013.SGD","BK4139","LU2210150020.SGD","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","SG9999014039.USD","LU2210149790.SGD","IE00BGHQF748.EUR","BK4588","CLDX"],"gpt_icon":0},{"id":"2614055618","title":"Celldex Therapeutics Q4 EPS USD -1.22 VS. Ibes Estimate USD -1.01","url":"https://stock-news.laohu8.com/highlight/detail?id=2614055618","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614055618?lang=en_us&edition=fundamental","pubTime":"2026-02-26 05:01","pubTimestamp":1772053261,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nPLXA24A53:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2614032685","title":"Celldex Therapeutics Up Over 19%, on Pace for Largest Percent Increase Since February 2024 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2614032685","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614032685?lang=en_us&edition=fundamental","pubTime":"2026-02-26 01:18","pubTimestamp":1772039880,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics, Inc.  is currently at $29.62, up $4.78 or 19.24%. --Would be highest close since Dec. 8, 2025, when it closed at $29.80. --On pace for largest percent increase since Feb. 26, 2024, when it rose 27.76%. --Currently up three consecutive days; up 28.67% over this period. --Up 20.41% month-to-date; on pace for best month since Feb. 2024, when it rose 36.46%. --Down 99.02% from its all-time closing high of $3015.00 on March 6, 2000. --Up 43.58% from 52 weeks ago , when it closed at $20.63. --Down 0.6% from its 52-week closing high of $29.80 on Dec. 8, 2025. --Up 95.77% from its 52-week closing low of $15.13 on April 8, 2025. --Traded as high as $29.77; highest intraday level since Dec. 9, 2025, when it hit $29.91. --Up 19.85% at today's intraday high; largest intraday percent increase since Feb. 26, 2024, when it rose as much as 29.7%","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CLDX"],"gpt_icon":0},{"id":"2614394460","title":"Celldex Shares Rise After Barzolvolimab Study Completes Enrollment Early","url":"https://stock-news.laohu8.com/highlight/detail?id=2614394460","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614394460?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:56","pubTimestamp":1772034960,"startTime":"0","endTime":"0","summary":"Celldex Therapeutics shares were 18% higher, at $29.34, after the company said it completed enrollment in its global Phase 3 program of barzolvolimab in chronic spontaneous urticaria six months ahead of previous guidance.The company said 1,939 patients were enrolled in 43 countries and more than 500 sites.Celldex said the Phase 3 program is designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic. The primary endpoint of the study will evaluate the clinical effect of barzolvolimab in reducing urticaria activity at week 12. The study is designed to detect a clinically meaningful difference between each of the active arms compared with placebo in the overall population as well as in the subpopulation of omalizumab refractory participants.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CLDX","BK4139"],"gpt_icon":0},{"id":"2614903923","title":"Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Celldex (CLDX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614903923","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614903923?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:50","pubTimestamp":1772034640,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ionis Pharmaceuticals (IONS – Research Report), Cell...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ionis-pharmaceuticals-ions-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ionis-pharmaceuticals-ions-celldex-cldx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BLSG","BLSX","BK4581","XBI","BK4139","BK4588","LU0128526141.USD","LU0029874061.USD","BK4137","BK4585","BK4112","CLDX","IONS","LABU"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.celldex.com","stockEarnings":[{"period":"1week","weight":0.0471},{"period":"1month","weight":0.3435},{"period":"3month","weight":0.207},{"period":"6month","weight":0.2556},{"period":"1year","weight":0.5543},{"period":"ytd","weight":0.1377}],"compareEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.055},{"period":"3month","weight":-0.047},{"period":"6month","weight":-0.0228},{"period":"1year","weight":0.1469},{"period":"ytd","weight":-0.0489}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.55,"avgChangeRate":0.123409},{"month":2,"riseRate":0.425,"avgChangeRate":-0.00139},{"month":3,"riseRate":0.475,"avgChangeRate":0.003913},{"month":4,"riseRate":0.487179,"avgChangeRate":0.002303},{"month":5,"riseRate":0.282051,"avgChangeRate":-0.021096},{"month":6,"riseRate":0.5,"avgChangeRate":0.145989},{"month":7,"riseRate":0.425,"avgChangeRate":-0.012999},{"month":8,"riseRate":0.375,"avgChangeRate":-0.027935},{"month":9,"riseRate":0.325,"avgChangeRate":-0.018185},{"month":10,"riseRate":0.5,"avgChangeRate":0.004664},{"month":11,"riseRate":0.575,"avgChangeRate":0.057317},{"month":12,"riseRate":0.45,"avgChangeRate":-0.008619}],"exchange":"NASDAQ","name":"Celldex Therapeutics","nameEN":"Celldex Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Celldex Therapeutics,CLDX,Celldex Therapeutics股票,Celldex Therapeutics股票老虎,Celldex Therapeutics股票老虎国际,Celldex Therapeutics行情,Celldex Therapeutics股票行情,Celldex Therapeutics股价,Celldex Therapeutics股市,Celldex Therapeutics股票价格,Celldex Therapeutics股票交易,Celldex Therapeutics股票购买,Celldex Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Celldex Therapeutics(CLDX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Celldex Therapeutics(CLDX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction